The GLP-1 pathway also slows gastric emptying, meaning food remains in the stomach longer, extending satiety after eating
[17] [16] Importantly, patients without baseline retinopathy did not demonstrate increased risk, and the overall cardiovascular benefits of semaglutide were maintained despite this ocular safety signal
Some (especially those who were detrained before starting) see modest strength increases despite caloric deficit
In the broader market, GLP-1 single-agonist formulations are commonly associated with semaglutide, the active ingredient in brand-name Wegovy, which is FDA-approved for chronic weight management
This means tirzepatide vials are generally larger, concentrations may be higher, and the unit volumes per dose are correspondingly different
This isn't just an old wives' tale